Matthew D. Hellmann, MD, on SCLC: Results From CheckMate 032

2017 ASCO Annual Meeting
Tweet this page

Matthew D. Hellmann, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)

Jul

Today In Oncology

American Cancer Society Outlines Blueprint for Cancer Control in the 21st Century

First-Line Treatment With Checkpoint Inhibitors in Patients With Melanoma Brain Metastases

Pazopanib Plus Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Somatic Driver Alterations and Distant Recurrence in Postmenopausal Early Breast Cancer Patients Receiving Endocrine Therapy

FDA Approves Enzalutamide for Castration-Resistant Prostate Cancer

;